On Thursday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Retrophin, Inc. (NASDAQ:RTRX), Endeavour Silver Corp. (NYSE:EXK), Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)
Retrophin, Inc. (NASDAQ:RTRX), with shares inclined 9.92%, closed at $22.17.
Endeavour Silver Corp. (NYSE:EXK), with shares jumped 9.57%, settled at $2.06.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), with shares climbed 9.17%, and closed at $5.24.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), surged 9.09%, and closed at $2.64.
Latest NEWS regarding these Stocks are depicted underneath:
Retrophin, Inc. (NASDAQ:RTRX)
Retrophin, Inc. (RTRX), a biopharmaceutical corporation focused on the discovery and development of drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening, and for which there are presently limited patient options, recently declared the pricing of an underwritten public offering of 6,840,000 shares of its ordinary stock at a price to the public of $19.00 per share. The gross proceeds to Retrophin from this offering, before deducting underwriting discounts and commissions and offering expenses payable by Retrophin, are predictable to be about $130.0 million. Retrophin has granted the underwriters a 30-day option to purchase up to an aggregate of 1,026,000 additional shares of ordinary stock. The offering is predictable to close on or about March 24, 2015, subject to customary closing conditions. Retrophin anticipates using the net proceeds from the offering to fund its research and development efforts, attainments or investments in additional complementary businesses, products and technologies, counting $27 million to fund the initial cash milestone payment payable in connection with the attainment of an additional clinical asset from Asklepion Pharmaceuticals, LLC, and for general corporate purposes, counting working capital.
Leerink Partners LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers for the offering. Nomura Securities International, Inc. and JMP Securities LLC are acting as co-managers for the offering.
Retrophin, Inc., a biopharmaceutical corporation, focuses on the development, attainment, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases.
Endeavour Silver Corp. (NYSE:EXK)
Endeavour Silver Corp. (EXK), has initiated a major expansion of its El Cubo mine in Guanajuato state, Mexico. The Corporation plans to ramp up mine output over the next four months from 1,550 tonnes per day (tpd), the current El Cubo plant capacity, to 2,200 tpd.
Revised Production Guidance:
The Corporation has revised its silver production estimate for 2015 upwards by 11% to a range of 6.3-7.0 million ounces (oz). Gold production guidance raises by 27% to the 60,000-66,000 oz range, and silver equivalent production is now forecast to be about 10.4-11.6 million oz (using a 70:1 silver:gold ratio).
Revised Operating Costs:
Merged cash costs of production, net of gold by-product credits, are now predictable to be around $9-$10 per oz of silver in 2015. Merged cash costs for silver and gold on a co-product basis should come in around $13-$14 and $900-$975 per oz respectively. The lower cash cost guidance is largely a function of reduced unit costs at El Cubo due to raised productivity related to the mine expansion.
All-in sustaining costs (AISC) net of gold by-product credits, in accordance with the World Gold Council standard, are now projected to be $16.00-$17.50 per oz of silver in 2015. Although the El Cubo mine expansion requires an raise in mine development capital, administration was able to reduce some minor capital projects to optimize the AISC. When non-cash items such as stock based compensation are excluded, AISC net of gold by-product credits should pull back to $15.50-$17.00 per oz of silver.
On a co-product basis, AISC are predicted to be $18.00-$19.00 per oz silver and $1,150-$1,200 per oz gold. Direct operating costs are estimated to be in the $87-$90 per tonne range.
Endeavour Silver Corp. engages in the evaluation, attainment, exploration, development, and exploitation of precious metal properties in Mexico and Chile.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Formerly on March 6, Aurinia Pharmaceuticals Inc. (AUPH), declared that Mr. Kurt von Emster has tendered his resignation as a member of the Aurinia Board of Directors, effective March 6th, 2015. This decision is driven by Mr. von Emster’s departure from the employment of venBio LLC (“venBio”), and the retained right of venBio to put forward a nominee of their choice for election onto the Aurinia Board of Directors.
“The Corporation very much wants to thank Kurt for his contributions and thoughtful input over the course of his tenure. We are very appreciative of everything that Kurt has brought to us,” said Dr. Richard Glickman, Chairman of Aurinia’s Board of Directors.
Aurinia is a clinical stage pharmaceutical corporation focused on the global nephrology market. It is presently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)
Formerly on March 12, Sunesis Pharmaceuticals, Inc. (SNSS), stated financial results for the fourth quarter and year ended December 31, 2014. Loss from operations for the three months and year ended December 31, 2014 was $11.2 million and $45.0 million, respectively. As of December 31, 2014, cash, cash equivalents and marketable securities totaled $43.0 million.
“The fourth quarter of 2014 was a focal period for Sunesis and vosaroxin, with unblinding of our Phase 3 VALOR trial in October and the presentation in December of the full results at the late breaking abstract forum of ASH,” said Daniel Swisher, Chief Executive Officer of Sunesis. “AML remains a challenging disease, with a striking absence of new therapeutic treatment options. In this context, we are engaged in active dialogue with regulators in Europe and the U.S. We remain on track to file an MAA in Europe in the second half of 2015, and look forward to providing clarity on our path forward in the U.S. around mid-year.”
Mr. Swisher continued: “In addition to VALOR, we are ongoing to make progress across our pipeline, counting in our investigator sponsored trials of vosaroxin and our kinase-inhibitor programs.”
Sunesis Pharmaceuticals, Inc., a biopharmaceutical corporation, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
